The FDA has granted 510(k) clearance to AdvanDx for updated versions of peptide nucleic acid fluorescence in situ hybridization tests, which can spot Escherichia coli/Pseudomonas aeruginosa and EK/P. aeruginosa in 90 minutes. "The FDA clearances ... bring AdvanDx a step closer to providing accurate and actionable results in just 90 minutes for the most critical bloodstream pathogens," said Thais Johansen, the company's president and CEO.

Related Summaries